Atnahs Pharma UK Limited – Trademark Portfolio
Entity Type: 99
Atnahs Pharma UK Limited holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include ATNAHS, ANAPROX, LEUSTATIN, PHARMANOVIA, and THE LIFE CYCLE MANAGEMENT COMPANY.
Sovereign House, Miles Gray Road,
Basildon Essex SS14 3FR
Showing of trademarks Trademarks
Trademark Classifications
Atnahs Pharma UK Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Atnahs Pharma UK Limited have?
Atnahs Pharma UK Limited has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does Atnahs Pharma UK Limited file in?
Atnahs Pharma UK Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Atnahs Pharma UK Limited's most well-known trademarks?
Atnahs Pharma UK Limited's registered trademark portfolio includes well-known marks such as ATNAHS, ANAPROX, LEUSTATIN, PHARMANOVIA, and THE LIFE CYCLE MANAGEMENT COMPANY. These are among 5 currently registered trademarks in the portfolio.
What is Atnahs Pharma UK Limited's trademark registration success rate?
Atnahs Pharma UK Limited has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.